

*This copy is for your personal, non-commercial use only.*

If you wish to distribute this article to others, you can order high-quality copies for your colleagues, clients, or customers by [clicking here](#).

Permission to republish or repurpose articles or portions of articles can be obtained by following the guidelines [here](#).

**The following resources related to this article are available online at [www.sciencemag.org](http://www.sciencemag.org) (this information is current as of November 10, 2010):**

**Updated information and services**, including high-resolution figures, can be found in the online version of this article at:

<http://www.sciencemag.org/cgi/content/full/327/5968/1000>

**Supporting Online Material** can be found at:

<http://www.sciencemag.org/cgi/content/full/327/5968/1000/DC1>

A list of selected additional articles on the Science Web sites **related to this article** can be found at:

<http://www.sciencemag.org/cgi/content/full/327/5968/1000#related-content>

This article **cites 11 articles**, 5 of which can be accessed for free:

<http://www.sciencemag.org/cgi/content/full/327/5968/1000#otherarticles>

This article has been **cited by** 2 article(s) on the ISI Web of Science.

This article has been **cited by** 7 articles hosted by HighWire Press; see:

<http://www.sciencemag.org/cgi/content/full/327/5968/1000#otherarticles>

This article appears in the following **subject collections**:

Cell Biology

[http://www.sciencemag.org/cgi/collection/cell\\_biol](http://www.sciencemag.org/cgi/collection/cell_biol)

histone marks, and an interacting splicing regulator (Fig. 5D). Such complexes are a means for epigenetic information to be transmitted to the pre-mRNA processing machinery and probably act by favoring the recruitment of specific splicing regulators to the pre-mRNA, thus defining splicing outcome. We show here that for a subset of PTB-dependent genes, this adaptor system consists of H3-K36me3, its binding protein MRG15, and the splicing regulator PTB. It is tempting to speculate that other combinations of adaptor systems exist that act on other types of alternatively spliced exons. Physical interaction between several chromatin-associated proteins and splicing components has been reported (9, 14). Our results are in line with recent indirect evidence based on genome-wide mapping of histone modifications for a role for chromatin structure and histone modifications in exon definition and alternative splice site selection (5, 13, 15–19).

Although our observations argue for a direct link between histone modifications and the splicing machinery, histone marks may also affect splice site choice indirectly. Extensive evidence demonstrates a role for RNA polymerase II elongation rate or higher-order chromatin structure in splicing outcome, and it is likely that histone modifications act in concert with these mechanisms (6–8, 10–12). Based on our findings, we propose that the epigenetic memory contained in histone modification patterns is not only used to determine the level of activity of a gene but also

transmits information to establish, propagate, and regulate AS patterns during physiological processes such as development and differentiation.

#### References and Notes

1. B. J. Blencowe, *Cell* **126**, 37 (2006).
2. A. J. Mattin, F. Clark, C. W. J. Smith, *Nat. Rev. Mol. Cell Biol.* **6**, 386 (2005).
3. E. T. Wang *et al.*, *Nature* **27**, 456 (2008).
4. G. S. Wang, T. A. Cooper, *Nat. Rev. Genet.* **8**, 749 (2007).
5. M. Alló *et al.*, *Nat. Struct. Mol. Biol.* **16**, 717 (2009).
6. E. Batsché, M. Yaniv, C. Muchardt, *Nat. Struct. Mol. Biol.* **13**, 22 (2006).
7. M. de la Mata *et al.*, *Mol. Cell* **12**, 525 (2003).
8. A. R. Kornblihtt, M. de la Mata, J. P. Fededa, M. J. Munoz, G. Nogues, *RNA* **10**, 1489 (2004).
9. R. J. Loomis *et al.*, *Mol. Cell* **33**, 450 (2009).
10. M. J. Muñoz *et al.*, *Cell* **137**, 708 (2009).
11. G. Nogues, S. Kadener, P. Cramer, D. Bentley, A. R. Kornblihtt, *J. Biol. Chem.* **277**, 43110 (2002).
12. N. D. Robson-Dixon, M. A. Garcia-Blanco, *J. Biol. Chem.* **279**, 29075 (2004).
13. I. E. Schor, N. Rascovan, F. Pelisch, M. Alló, A. R. Kornblihtt, *Proc. Natl. Acad. Sci. U.S.A.* **106**, 4325 (2009).
14. R. J. Sims 3rd *et al.*, *Mol. Cell* **28**, 665 (2007).
15. R. Andersson, S. Enroth, A. Rada-Iglesias, C. Wadelius, J. Komorowski, *Genome Res.* **19**, 1732 (2009).
16. P. Kolasinska-Zwiercz *et al.*, *Nat. Genet.* **41**, 376 (2009).
17. S. Schwartz, E. Meshorer, G. Ast, *Nat. Struct. Mol. Biol.* **16**, 990 (2009).
18. N. Spies, C. B. Nielsen, R. A. Padgett, C. B. Burge, *Mol. Cell* **36**, 245 (2009).
19. H. Tilgner *et al.*, *Nat. Struct. Mol. Biol.* **16**, 996 (2009).
20. R. P. Carstens, E. J. Wagner, M. A. Garcia-Blanco, *Mol. Cell Biol.* **20**, 7388 (2000).
21. C. C. Warzecha, T. K. Sato, B. Nabet, J. B. Hogenesch, R. P. Carstens, *Mol. Cell* **33**, 591 (2009).

22. E. J. Wagner, M. A. Garcia-Blanco, *Mol. Cell* **10**, 943 (2002).
23. R. Spelman, M. Llorian, C. W. J. Smith, *Mol. Cell* **27**, 420 (2007).
24. T. Hayakawa *et al.*, *Genes Cells* **12**, 811 (2007).
25. P. Zhang *et al.*, *Nucleic Acids Res.* **34**, 6621 (2006).
26. Q. Pan *et al.*, *Mol. Cell* **16**, 929 (2004).
27. Q. Pan, O. Shai, L. J. Lee, B. J. Frey, B. J. Blencowe, *Nat. Genet.* **40**, 1413 (2008).
28. D. Ray *et al.*, *Nat. Biotechnol.* **27**, 667 (2009).
29. We thank J. Patton, D. Skalik, B. Strahl, J. Steitz, D. Black, M. Garcia-Blanco, and H. Kimura for reagents; P. Scaffidi for discussions; J. Calarco for validations; C. Misquitta for technical assistance; H. Kosucu and Q. Morris for advice on statistical analysis; and E. Tominaga for cell culture. This research was supported by the Intramural Research Program of NIH, the National Cancer Institute, the Center for Cancer Research (T.M.), grants from the National Cancer Institute of Canada, Canadian Institutes of Health Research (grant MOP-67011) and Genome Canada (administered through the Ontario Genomics Institute) to B.B., NIA/NIH grant RO1 AG032134 (OMPS) to O.P.S., and American Heart Association grant 0765084Y to K.T. Complete RNA deep-sequencing data are available at the Gene Expression Omnibus (accession no. GSE19373).

#### Supporting Online Material

www.sciencemag.org/cgi/content/full/science.1184208/DC1  
Materials and Methods  
Figs. S1 to S13  
Tables S1 and S2  
References

4 November 2009; accepted 17 December 2009  
Published online 4 February 2010;  
10.1126/science.1184208  
Include this information when citing this paper.

## Regulation of Cellular Metabolism by Protein Lysine Acetylation

Shimin Zhao,<sup>1,2</sup> Wei Xu,<sup>1,2\*</sup> Wenqing Jiang,<sup>1,2\*</sup> Wei Yu,<sup>1,2</sup> Yan Lin,<sup>2</sup> Tengfei Zhang,<sup>1,2</sup> Jun Yao,<sup>3</sup> Li Zhou,<sup>4</sup> Yaxue Zeng,<sup>4</sup> Hong Li,<sup>5</sup> Yixue Li,<sup>6</sup> Jiong Shi,<sup>6</sup> Wenlin An,<sup>7</sup> Susan M. Hancock,<sup>7</sup> Fuchu He,<sup>3</sup> Lunxiu Qin,<sup>5</sup> Jason Chin,<sup>7</sup> Pengyuan Yang,<sup>3</sup> Xian Chen,<sup>3,4</sup> Qunying Lei,<sup>1,2,8</sup> Yue Xiong,<sup>1,2,4,†</sup> Kun-Liang Guan<sup>1,2,8,9,†</sup>

Protein lysine acetylation has emerged as a key posttranslational modification in cellular regulation, in particular through the modification of histones and nuclear transcription regulators. We show that lysine acetylation is a prevalent modification in enzymes that catalyze intermediate metabolism. Virtually every enzyme in glycolysis, gluconeogenesis, the tricarboxylic acid (TCA) cycle, the urea cycle, fatty acid metabolism, and glycogen metabolism was found to be acetylated in human liver tissue. The concentration of metabolic fuels, such as glucose, amino acids, and fatty acids, influenced the acetylation status of metabolic enzymes. Acetylation activated enoyl-coenzyme A hydratase/3-hydroxyacyl-coenzyme A dehydrogenase in fatty acid oxidation and malate dehydrogenase in the TCA cycle, inhibited argininosuccinate lyase in the urea cycle, and destabilized phosphoenolpyruvate carboxykinase in gluconeogenesis. Our study reveals that acetylation plays a major role in metabolic regulation.

Protein acetylation has a key role in the regulation of transcription in the nucleus (1), but much less is known about non-nuclear protein acetylation and its role in cellular regulation. To investigate non-nuclear protein acetylation, we separated human liver tissues into nuclear, mitochondrial, and cytosolic fractions. Proteins in cytosolic and mitochondrial fractions were digested with trypsin and acetylated peptides were purified with an antibody to acetyllysine

(fig. S1). The purified peptides were analyzed by tandem liquid chromatography–tandem mass spectrometry (LC/LC-MS/MS). From three independent experiments, we identified more than 1300 acetylated peptides, which matched to 1047 distinct human proteins (table S1), including 703 proteins not previously reported to be acetylated. A previous report identified 195 acetylated proteins from mouse liver (2), and 135 (70%) of these were also present in our data set (Fig. 1A),

indicating that our proteomic analysis reached a high degree of coverage. Choudhary *et al.* very recently reported the identification of 1750 acetylated proteins from a human leukemia cell line (3), but only 240 of these were present in our data set (Fig. 1A). Comparison of these three acetylome data sets indicates that the spectrum of acetylated proteins is highly conserved in the liver between mouse and human, but is very different between liver and leukemia cells.

We compared the acetylated proteins with the total liver proteome and discovered that enzymes that participate in intermediate metabolism were preferentially acetylated (Fig. 1B). Indeed, almost

<sup>1</sup>School of Life Sciences, Fudan University, Shanghai 20032, China. <sup>2</sup>Molecular and Cell Biology Lab, Fudan University, Shanghai 20032, China. <sup>3</sup>Center of Proteomics, Institute of Biomedical Sciences, Fudan University, Shanghai 20032, China. <sup>4</sup>Department of Biochemistry and Biophysics, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA. <sup>5</sup>Affiliated Zhongshan Hospital, Fudan University, Shanghai 20032, China. <sup>6</sup>Bioinformatics Center, Key Lab of Systems Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China. <sup>7</sup>Medical Research Council Laboratory of Molecular Biology, Hills Road, Cambridge CB2 0QH, UK. <sup>8</sup>Department of Biological Chemistry, Fudan University, Shanghai 20032, China. <sup>9</sup>Department of Pharmacology and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA.

\*These authors contributed equally to this work.

†To whom correspondence should be addressed. E-mail: yxiong@email.unc.edu (Y.X.); kuguan@ucsd.edu (K.L.G.)

every enzyme in glycolysis, gluconeogenesis, the TCA cycle, the urea cycle, fatty acid metabolism, and glycogen metabolism was acetylated (Fig. 1, C to G). The high occurrence of metabolic enzymes identified in our MS analysis is apparently not due to the abundance of these proteins, because only a few ribosomal proteins (7 of approximately 80 cytosolic ribosomal proteins) were acetylated (table S1). These results indicate a previously unrecognized and potentially extensive role of acetylation in regulation of cellular metabolism. Therefore, we investigated the effect of acetylation on representative enzymes from four metabolic pathways.

Enoyl-coenzyme A hydratase/3-hydroxyacyl-coenzyme A (EHHADH; EC code 1.1.1.35) catalyzes two steps in fatty acid oxidation (Fig. 1E) (4, 5), and its deficiency causes abnormal fatty acid metabolism (6). We identified four acetylated lysine residues (Lys<sup>165</sup>, Lys<sup>171</sup>, Lys<sup>346</sup>, and Lys<sup>584</sup>) in EHHADH (table S2). Immunoprecipitation of ectopically expressed FLAG-tagged EHHADH and Western blotting with antibody to acetyllysine confirmed that EHHADH was in-


deed acetylated. Its acetylation was enhanced by 80% after treatment of cells with trichostatin A [TSA, an inhibitor of histone deacetylase (HDAC) I and II] and nicotinamide (NAM, an inhibitor of the SIRT family deacetylases) (Fig. 2A and fig. S2A). To quantify the acetylation of EHHADH, we used isobaric tags for relative and absolute quantitation (iTRAQ) MS of immunoprecipitated EHHADH. TSA and NAM treatment increased Lys<sup>171</sup> acetylation from 43.5% to 62% and Lys<sup>346</sup> acetylation from 46.8% to 77.8% (Fig. 2B), respectively. Consistently, the corresponding unacetylated peptides were decreased by TSA and NAM treatment. These results show that a substantial portion of EHHADH is acetylated and that EHHADH acetylation can be dynamically regulated in vivo.

To determine the effect of acetylation on enzymatic activity, we treated cultured Chang human liver cells with TSA and NAM and detected a doubling of endogenous EHHADH activity (Fig. 2C). Similar observations were also made with ectopically expressed EHHADH in HEK293T cells (Fig. 2C, right panel). Acetylation of an EHHADH<sup>4KQ</sup> mutant, which had the four puta-

tive acetylation lysine residues replaced by glutamine, was decreased (fig. S2C) and its activity was no longer regulated by TSA and NAM (Fig. 2C). Addition of fatty acids to the culture medium increased acetylation and activity of EHHADH by factors of 1.7 and 1.3, respectively (Fig. 2D and fig. S2D). Thus, acetylation of EHHADH can be regulated by extracellular fuels; this finding supports a physiological role of acetylation in the regulation of EHHADH and fatty acid metabolism.

All seven enzymes in the TCA cycle were acetylated (Fig. 1C and table S1), including malate dehydrogenase (MDH; EC code 1.1.1.37), in which four acetylated lysines were identified (Lys<sup>185</sup>, Lys<sup>301</sup>, Lys<sup>307</sup>, and Lys<sup>314</sup>; tables S2 and S3). Ectopically expressed MDH was acetylated and its acetylation was increased by a factor of 2.4 in cells treated with TSA and NAM (Fig. 2E and fig. S2E). To quantify MDH acetylation, we performed Fourier transform ion cyclotron resonance (FTICR) MS. This approach identified the unmodified full-length MDH and two additional peaks, each with a mass increment of 42.01 daltons, corresponding to mono- and diacetylation


**Fig. 1.** Acetylation of liver metabolic enzymes. **(A)** Comparison of three acetylation proteomic studies: this study and (2, 3). **(B)** Preferential acetylation of enzymes in intermediary metabolism. Fisher's exact test of comparing acetylated proteins to total liver proteins shows that acetylation is much more prevalent in intermediary metabolic enzymes. **(C to G)** Acetylated metabolic enzymes identified by proteomic survey are marked in red. See supporting online material for key to abbreviations.








**Fig. 3.** Inactivation of ASL by acetylation. **(A and B)** ASL acetylation. FLAG-tagged ASL or ASL<sup>K288R</sup> was overexpressed in HEK293T cells, immunoprecipitated, and probed with antibody to acetyllysine (A) or to acetyl-Lys<sup>288</sup> (B). **(C)** Inhibition of ASL acetylation by extra amino acids. ASL was immunoprecipitated from transfected HEK293T cells, which were treated with various amino acid concentrations. **(D)** Inhibition of ASL in response to NAM and TSA. Wild-type and mutant ASL-K288R (13.2% of wild-type activity) proteins were expressed in HEK293T cells that were treated with NAM and TSA as indicated. Activity of immunoprecipitated ASL was normalized to total protein. **(E)** Requirement of Lys<sup>288</sup> acetylation for ASL activation by amino acids. Wild-type and mutant ASL proteins were overexpressed in HEK293T cells incubated in medium containing various amino acid concentrations. **(F and G)** Effects of glucose on acetylation and activity of ASL. ASL was



overexpressed in HEK293T cells that were treated with various concentrations of glucose. Acetylation and activity of immunoprecipitated ASL were determined. **(H)** Activation of ASL by in vitro deacetylation. In vitro deacetylation was similar to Fig. 2I.



**Fig. 4.** Destabilization of PEPCK1 by acetylation. **(A)** Glucose induces PEPCK1 acetylation. **(B)** Amino acids decrease PEPCK1 acetylation. **(C)** Glucose induces depletion in of PEPCK1 protein. Endogenous PEPCK levels were detected with a PEPCK1 antibody. **(D)** TSA and NAM reduce PEPCK1 protein abundance. **(E)** Glucose destabilizes PEPCK1. Cycloheximide was added at time zero to block translation in HEK293 cells. PEPCK1 protein abundance was determined by Western blotting. **(F)** Inhibition of deacetylases destabilizes the wild type but not the acetylation-defective mutant PEPCK1.

mammalian cells with CobB deacetylase increased ASL activity (Fig. 3H), supporting a direct role of acetylation in ASL inactivation. The dual regulation of ASL by both amino acids and glucose indicates that acetylation may have an important role in the coordination of metabolic pathways. In the presence of sufficient glucose, amino acid catabolism for energy production and gluconeogenesis would be inhibited. In the presence of abundant amino acids and low glucose, cells would switch to using amino acids for energy production with enhanced urea cycle activity. Cells may use acetylation to coordinate multiple pathways in order to achieve these metabolic adaptations

Phosphoenolpyruvate carboxykinase 1 (PEPCK1; EC code 4.1.1.32) is a key regulatory enzyme in gluconeogenesis (Fig. 1D) (9, 10). Three acetylated lysine residues were identified in PEPCK1 by MS analysis (Lys<sup>70</sup>, Lys<sup>71</sup>, and Lys<sup>594</sup>; table S2). Acetylation of PEPCK1 was enhanced in cells treated with high concentrations of glucose (Fig. 4A) but was decreased by addition of amino acids in glucose-free medium (Fig. 4B). These results suggest a potential mechanism by which cells could regulate gluconeogenesis through regulating acetylation of PEPCK1 in response to the availability of extracellular fuels.

In searching for an effect of acetylation on the regulation of PEPCK1, we noticed that levels of endogenous PEPCK1 protein were decreased by high glucose (Fig. 4C). Furthermore, treatment with TSA and NAM caused a 70% reduction in the amount of PEPCK1 protein in both HEK293T and Chang liver cells (Fig. 4D). PEPCK1 was stable in cells in glucose-free medium but unstable

in high-glucose medium (Fig. 4E). When cells were treated with TSA and NAM, PEPCK1 was unstable even in glucose-free medium or in the presence of amino acids. These results indicate that acetylation may regulate the stability of PEPCK1. We replaced the three putative acetylation lysine residues by arginine (PEPCK1<sup>3KR</sup>) or glutamine (PEPCK1<sup>3KQ</sup>) to abolish or mimic acetylation, respectively. The PEPCK1<sup>3KR</sup> mutant was more stable than the wild type, whereas the PEPCK1<sup>3KQ</sup> mutant remained unstable (Fig. 4F). Moreover, treatment of cells with TSA and NAM failed to destabilize the PEPCK1<sup>3KR</sup> mutant.

The importance of lysine acetylation in the regulation of chromatin dynamics and gene expression is well appreciated. Our study and others extend the scope of cell regulation by lysine acetylation to an extent comparable to that of other major posttranslational modifications such as phosphorylation and ubiquitination. We show that most intermediate metabolic enzymes are acetylated and that acetylation can directly affect the enzyme activity or stability. We found that acetylation of metabolic enzymes changed in response to the alterations of extracellular nutrient availability, providing evidence for a physiological role of dynamic acetylation in metabolic regulation. The mechanism of acetylation in regulating metabolism may be conserved during evolution. Many metabolic enzymes in *Escherichia coli* are acetylated, although the functional importance of these acetylations has not been investigated (11). We propose that lysine acetylation is an evolutionarily conserved mechanism involved in regulation of metabolism in response to nutrient availability

and cellular metabolic status. Acetylation may play a key role in the coordination of different metabolic pathways in response to extracellular conditions.

#### References and Notes

1. X. J. Yang, E. Seto, *Mol. Cell* **31**, 449 (2008).
2. S. C. Kim *et al.*, *Mol. Cell* **23**, 607 (2006).
3. C. Choudhary *et al.*, *Science* **325**, 834 (2009).
4. K. Alvares *et al.*, *Cancer Res.* **54**, 2303 (1994).
5. C. S. Yeh *et al.*, *Cancer Lett.* **233**, 297 (2006).
6. P. A. Watkins *et al.*, *J. Clin. Invest.* **83**, 771 (1989).
7. E. Trevisson *et al.*, *Hum. Mutat.* **28**, 694 (2007).
8. R. L. Jungas, M. L. Halperin, J. T. Brosnan, *Physiol. Rev.* **72**, 419 (1992).
9. H. Lardy, P. E. Hughes, *Curr. Top. Cell. Regul.* **24**, 171 (1984).
10. P. She *et al.*, *Mol. Cell. Biol.* **20**, 6508 (2000).
11. J. Zhang *et al.*, *Mol. Cell. Proteomics* **8**, 215 (2009).
12. We thank members of Fudan MCB laboratory for their valuable inputs throughout this study and S. Jackson for reading the manuscript. Supported by the 985 program from the Chinese Ministry of Education, state key development programs of basic research of China (grants 2009CB918401 and 2006CB806700), the national high technology research and development program of China (grant 2006AA02A308), Chinese National Science Foundation grants 30600112 and 30871255, Shanghai key basic research projects (grants 06JC14086, 07PJ14011, 08JC1400900), and NIH grants R01GM51586, R01CA108941, and R01CA65572 (K.L.G., X.C., and Y.X.).

#### Supporting Online Material

www.sciencemag.org/cgi/content/full/327/5968/1000/DC1  
Materials and Methods

Figs. S1 to S3

Tables S1 to S3

References

27 July 2009; accepted 7 January 2010

10.1126/science.1179689

## Acetylation of Metabolic Enzymes Coordinates Carbon Source Utilization and Metabolic Flux

Qijun Wang,<sup>1</sup> Yakun Zhang,<sup>2</sup> Chen Yang,<sup>3</sup> Hui Xiong,<sup>1,2</sup> Yan Lin,<sup>4</sup> Jun Yao,<sup>4</sup> Hong Li,<sup>3</sup> Lu Xie,<sup>3</sup> Wei Zhao,<sup>3</sup> Yufeng Yao,<sup>5</sup> Zhi-Bin Ning,<sup>3</sup> Rong Zeng,<sup>3</sup> Yue Xiong,<sup>4,6</sup> Kun-Liang Guan,<sup>4,7</sup> Shimin Zhao,<sup>1,4\*</sup> Guo-Ping Zhao<sup>1,2,3,8\*</sup>

Lysine acetylation regulates many eukaryotic cellular processes, but its function in prokaryotes is largely unknown. We demonstrated that central metabolism enzymes in *Salmonella* were acetylated extensively and differentially in response to different carbon sources, concomitantly with changes in cell growth and metabolic flux. The relative activities of key enzymes controlling the direction of glycolysis versus gluconeogenesis and the branching between citrate cycle and glyoxylate bypass were all regulated by acetylation. This modulation is mainly controlled by a pair of lysine acetyltransferase and deacetylase, whose expressions are coordinated with growth status. Reversible acetylation of metabolic enzymes ensure that cells respond environmental changes via promptly sensing cellular energy status and flexibly altering reaction rates or directions. It represents a metabolic regulatory mechanism conserved from bacteria to mammals.

Protein lysine acetylation regulates wide range of cellular functions in eukaryotes, especially transcriptional control in the nucleus (1, 2). It also plays an extensive role in regulation of metabolic enzymes through vari-

ous mechanisms in human liver (3). In prokaryotes such as *Salmonella enterica*, reversible lysine acetylation is known to regulate the activity of acetyl-coenzyme A (CoA) synthetase (4). To determine how lysine acetylation globally regulates

the metabolism in prokaryotes, we determined the overall acetylation status of *S. enterica* proteins under either fermentable glucose-based glycolysis or under oxidative citrate-based gluconeogenesis. By immunopurification of acetylated peptides with antibody to acetyllysine and peptide identification

<sup>1</sup>State Key Laboratory of Genetic Engineering, Department of Microbiology, School of Life Sciences and Institute of Biomedical Sciences, Fudan University, Shanghai 200032, China. <sup>2</sup>MOST-Shanghai Laboratory of Disease and Health Genomics, Chinese National Human Genome Center at Shanghai, Shanghai 201203, China. <sup>3</sup>Key Laboratory of Synthetic Biology, Bioinformatics Center and Laboratory of Systems Biology, Institute of Plant Physiology and Ecology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200032, China. <sup>4</sup>Molecular Cell Biology Laboratory, Institute of Biomedical Sciences, Fudan University, Shanghai 200032, China. <sup>5</sup>Laboratory of Human Bacterial Pathogenesis, Department of Medical Microbiology and Parasitology, Institute of Medical Sciences, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China. <sup>6</sup>Department of Biochemistry and Biophysics and Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. <sup>7</sup>Department of Pharmacology and Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA. <sup>8</sup>Department of Microbiology and Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, China.

\*To whom correspondence should be addressed. E-mail: zhaosm@fudan.edu.cn (S.Z.); gpzhao@sibs.ac.cn (G.-P.Z.)